<DOC>
	<DOC>NCT00347100</DOC>
	<brief_summary>Primary: - To investigate the efficacy of insulin glargine (in terms of change in A1c from baseline to endpoint A1c &lt; 7%) Secondary: - To investigate the safety of insulin glargine (in terms of hypoglycaemia, including symptomatic, non-symptomatic and nocturnal hypoglycaemia) - To investigate whether beta cell function is preserved if this therapy is initiated before 2nd OAD (oral anti-diabetic drug) failure</brief_summary>
	<brief_title>Insulin Glargine in Type 2 Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Gliclazide</mesh_term>
	<mesh_term>Glipizide</mesh_term>
	<criteria>Type 2 diabetes patients with first OAD (Sulfonylurea [SU] or Metformin) failure Patients who are insulin naive (unless it was used for gestational diabetes or if insulin therapy was less than 1 week) Serum creatinine ≤ 1.5mg/dL BMI: 2141 kg/m² 7.5%&lt; A1c &lt;11% Fasting plasma glucose &gt; 7.5mmol/L On diet and exercise therapy and stable OAD treatment (SU or metformin &gt; ½ maximal dose)for more than 1 month prior to enrolment Women not of childbearing potential (sterilization procedure done or menopausal &gt; 2 years), or if of childbearing potential, agree to take reliable contraceptive measures during the study Able and willing to monitor blood glucose Able and willing to perform 7 point blood glucose self monitoring at baseline, 12 week and 24 week Understand that there is a 50% chance of being randomized to the insulin treatment arm and is willing to self inject insulin Type 1 diabetes Acute complication of diabetes, such as diabetic ketoacidosis and hyperosmolar coma Pregnancy, breastfeeding People who work night shifts Hypersensitivity to investigational drugs or its additives, or intolerability to metformin Need for use of medications prohibited by the protocol during the study for treatment purpose Significant diseases in cardiovascular, liver, nerve, endocrine or other systems, unable to complete the study or difficult to be used in study analysis Drugs or alcohol abuse The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>